Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$973.80 USD

973.80
351,356

+5.80 (0.60%)

Updated May 10, 2024 04:00 PM ET

After-Market: $972.97 -0.83 (-0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for REGN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Regeneron Pharmaceuticals, Inc. [REGN]

Reports for Purchase

Showing records 521 - 540 ( 591 total )

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 521

02/19/2013

Company Report

Pages: 4

Eylea Programs Continue to Expand; Buy on Recent Selloff

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 522

02/18/2013

Company Report

Pages: 7

Price: 24.95

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 523

02/15/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 524

02/14/2013

Company Report

Pages: 8

2012 Results; Ante Up for Future Growth and on Today''s Weakness

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 525

02/06/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 526

02/05/2013

Company Report

Pages: 4

Zaltrap Approved in Europe; Nice Headline but Focus on Eylea and PCSK9

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 527

01/23/2013

Company Report

Pages: 9

Price: 24.95

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 528

01/09/2013

Daily Note

Pages: 8

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 529

01/08/2013

Company Report

Pages: 7

Eylea Wows Yet Again, Poised for Blockbuster Status

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 530

11/05/2012

Company Report

Pages: 7

Important PCSK9 Visibility; Deep Commitment from Sanofi

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 531

11/01/2012

Company Report

Pages: 8

Price: 24.95

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 532

10/25/2012

Daily Note

Pages: 14

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 533

10/24/2012

Company Report

Pages: 8

3Q12 Results; EYLEA Guidance Upped Again; Target to $181

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 534

10/10/2012

Company Report

Pages: 8

Price: 24.95

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 535

09/28/2012

Company Report

Pages: 6

Eylea Approved in Japan for Wet AMD; Target to $170.

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 536

09/28/2012

Daily Note

Pages: 15

MORNING CALL SUMMARY.

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 537

09/24/2012

Daily Note

Pages: 11

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 538

09/21/2012

Company Report

Pages: 4

Positive CHMP Opinion for Eylea in the E.U. for Wet AMD

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 539

09/21/2012

Daily Note

Pages: 9

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 540

09/21/2012

Company Report

Pages: 6

Eylea Approved in CRVO, as Anticipated; Raising PT to $162

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party